Department of Clinical Oncology, Cancer Diseases Hospital, Lusaka, Zambia
Case Report
Lutetium 177 PMSA Therapy for Metastatic Castrate Resistant Prostate Cancer: A Zambian Case Report
Author(s): Maurice Mwale*, Joseph Kabunda, Susan Msadabwe and Davie Mulenga
Targeted therapies such as Lutetium 177 PSMA therapy offer alternatives to the treatment of metastatic castrate resistant prostate cancer patients. Here, we present a 63 years old black Zambian male patient who initially diagnosed with high risk prostate cancer. The patient failed the initial treatments and presented with severe bone pains with spinal cord compression. He was then considered for PSMA lutetium therapy after multiple therapies and disease progression to metastatic castrate resistant setting. The patient’s performance status improved dramatically after this treatment and was able to return to work without any pains and is fully ambulant. PSMA-targeted therapy is a promising approach in the management of metastatic castrate resistant prostate cancer. The access to such therapies is however limited especially in low limited resource areas which includes Zambia. There.. View More»
DOI:
10.35248/2471-8556.25.11(1).002